Globus Medical (NYSE:GMED) Director Sells $2,176,000.00 in Stock

Key Points

• Director Stephen Zarrilli sold 25,000 Globus Medical shares for approximately $2.18 million, reducing his position by 50%.
• Globus Medical shares rose 2.4% to $88.48, while the company reported quarterly EPS of $1.34—beating estimates by $0.24—and revenue of $789.6 million, up 5.9% year over year.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $101.77, and institutional investors own 95.16% of the company’s outstanding shares.

Globus Medical, Inc. (NYSE:GMED - Get Free Report) Director Stephen Zarrilli sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total value of $2,176,000.00. Following the transaction, the director owned 25,000 shares of the company's stock, valued at $2,176,000. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Globus Medical Stock Up 2.4%

NYSE:GMED traded up $2.04 during trading hours on Wednesday, reaching $88.48. The company had a trading volume of 1,063,950 shares, compared to its average volume of 1,496,449. The stock has a 50-day moving average of $80.20 and a two-hundred day moving average of $84.81. Globus Medical, Inc. has a one year low of $54.15 and a one year high of $101.40. The firm has a market capitalization of $11.88 billion, a PE ratio of 22.63, a PEG ratio of 1.38 and a beta of 0.95.

Globus Medical (NYSE:GMED - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.10 by $0.24. The company had revenue of $789.61 million during the quarter, compared to analysts' expectations of $782.88 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%.The business's revenue was up 5.9% on a year-over-year basis. During the same period last year, the business earned $0.86 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, sell-side analysts expect that Globus Medical, Inc. will post 4.99 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on GMED shares. Zacks Research raised Globus Medical from a "hold" rating to a "strong-buy" rating in a research note on Monday, August 10th. Needham & Company LLC upped their price target on shares of Globus Medical from $114.00 to $117.00 and gave the stock a "buy" rating in a research report on Friday, May 8th. Royal Bank Of Canada decreased their price objective on shares of Globus Medical from $120.00 to $115.00 and set an "outperform" rating on the stock in a report on Monday, July 13th. Piper Sandler reduced their target price on shares of Globus Medical from $115.00 to $100.00 and set an "overweight" rating on the stock in a research report on Monday, June 15th. Finally, Truist Financial decreased their price target on shares of Globus Medical from $115.00 to $100.00 and set a "buy" rating on the stock in a research note on Thursday, July 16th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $101.77.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. grew its holdings in Globus Medical by 71,618.6% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 716,469 shares of the medical device company's stock valued at $62,555,000 after purchasing an additional 715,470 shares during the period. WCM Investment Management LLC acquired a new position in shares of Globus Medical in the 1st quarter valued at $16,965,000. SG Americas Securities LLC increased its position in shares of Globus Medical by 241.1% in the 1st quarter. SG Americas Securities LLC now owns 340,452 shares of the medical device company's stock valued at $29,333,000 after buying an additional 240,642 shares in the last quarter. Artemis Investment Management LLP raised its stake in Globus Medical by 43.7% during the 4th quarter. Artemis Investment Management LLP now owns 738,595 shares of the medical device company's stock worth $64,487,000 after buying an additional 224,587 shares during the period. Finally, Hyperion Capital Advisors LP bought a new position in Globus Medical during the fourth quarter worth about $12,822,000. 95.16% of the stock is currently owned by institutional investors.

About Globus Medical

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source